



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/578,013
Filing Date	May 3, 2006
First Named Inventor	Robert F. Garry
Art Unit	1648
Examiner Name	
Attorney Docket Number	12920.0013.PCUS00

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/NK/	C1	ATABANI, et al., Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection, Journal of Virology, 1997, 71(10):7240-7245.	
/NK/	C2	SAMUEL, et al., Participation of two fusion peptides in measles virus-induced membrane fusion: emerging similarity with other paramyxoviruses, Biochemistry, 2001, 40:1340-1349.	
/NK/	C3	KLIGER, et al., Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy, BMC Microbiology, 2003, 3:20.	

Examiner Signature	/Nicole Kinsey/	Date Considered	11/16/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Form PTO-1449 (modified)

Atty. Docket No.
12920.0013.PCUS00Serial No.
10/578,013

List of Patents and Publications for Applicant's

Applicant
Robert F. Garry, Russell B. Wilson

INFORMATION DISCLOSURE STATEMENT

Filing Date:
May 3, 2006Group:
1648

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Pages 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						
	A2						
	A3						
	A4						

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
/NK/	B3	WO 01/59457 A2	08/16/2001	WIPO	G01N	33/569	
/NK/	B4	WO 88/08429	11/03/1988	WIPO	C07K	7/08	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/NK/	C4	CHAN, et al., Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target, (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95, 15613-15617.
/NK/	C5	CARR, et al., A spring-loaded mechanism for the conformational change of influenza hemagglutinin, (1993). <i>Cell</i> 73, 823-832.
/NK/	C6	FASS, et al., Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin, (1995). <i>Current Biology</i> 5, 1377-1383.
/NK/	C7	CLEGG, et al., Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products, (1991). <i>Virus Research</i> 18, 151-164.

EXAMINER: /Nicole Kinsey/

DATE CONSIDERED: 11/16/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

DM_US:20636446_1

